Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLSNASDAQ:CLYMNASDAQ:IZTCNASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$1.45+0.5%$1.43$1.10▼$2.78$80.43M3.11143,869 shs103,936 shsCLYMClimb Bio$1.21-0.8%$1.24$1.05▼$9.58$81.77M-0.12275,486 shs109,509 shsIZTCInvizyne Technologies$13.40-3.6%$12.06$8.50▼$23.00$83.78MN/A37,647 shs3,738 shsMTEXMannatech$9.86+3.7%$9.76$6.75▼$16.49$18.74M1.064,426 shs2,096 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis0.00%-1.56%-10.29%+12.17%-46.80%CLYMClimb Bio0.00%+2.54%-3.97%-16.55%+120,999,900.00%IZTCInvizyne Technologies-3.60%-10.07%+21.82%-20.71%+1,339,999,900.00%MTEXMannatech0.00%+0.09%-3.20%-12.75%+28.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis3.1583 of 5 stars3.55.00.00.01.92.50.6CLYMClimb Bio2.8697 of 5 stars3.70.00.00.02.02.51.3IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AMTEXMannatech1.0125 of 5 stars0.04.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$7.00383.76% UpsideCLYMClimb Bio 3.33Buy$8.50602.48% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/AMTEXMannatech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MTEX, CLLS, CLYM, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025CLYMClimb BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025CLYMClimb BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$7.005/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$47.63M1.69N/AN/A$1.52 per share0.95CLYMClimb BioN/AN/AN/AN/A$3.90 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AMTEXMannatech$115.04M0.16N/AN/A$5.64 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$101.06M-$0.86N/AN/AN/A-234.39%-74.55%-22.65%8/5/2025 (Estimated)CLYMClimb Bio-$35.12M-$2.38N/AN/AN/AN/A-42.21%-41.39%8/13/2025 (Estimated)IZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AMTEXMannatech-$2.24M-$0.10N/A∞N/A-1.26%-15.62%-3.76%8/11/2025 (Estimated)Latest MTEX, CLLS, CLYM, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CLYMClimb Bio-$0.15-$0.31-$0.16-$0.31N/AN/A5/13/2025Q1 2025MTEXMannatechN/A-$0.80N/A-$0.80N/A$26.56 million5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million3/26/2025Q4 2024MTEXMannatechN/A$1.20N/A$1.20N/A$29.01 million3/25/2025Q4 2024CLYMClimb Bio-$0.15-$0.13+$0.02-$0.13N/AN/A3/13/2025Q4 2024CLLSCellectis$0.06-$0.16-$0.22-$0.15$5.90 million$33.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AMTEXMannatech$0.202.03%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.481.781.78CLYMClimb BioN/A57.7357.73IZTCInvizyne TechnologiesN/AN/AN/AMTEXMannatech0.441.250.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%CLYMClimb Bio69.76%IZTCInvizyne TechnologiesN/AMTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%CLYMClimb Bio0.80%IZTCInvizyne TechnologiesN/AMTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableCLYMClimb Bio967.58 million65.07 millionN/AIZTCInvizyne TechnologiesN/A6.25 millionN/AN/AMTEXMannatech2501.90 million1.10 millionNot OptionableMTEX, CLLS, CLYM, and IZTC HeadlinesRecent News About These CompaniesMannatech (NASDAQ:MTEX) Now Covered by Analysts at Wall Street ZenMay 23, 2025 | americanbankingnews.comMannatech Premieres Powerful New Documentary on Marathon Legend Steve EdwardsMay 21, 2025 | businesswire.comMannatech Reports Financial Results for First Quarter 2025May 13, 2025 | businesswire.comAstronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancementsApril 14, 2025 | msn.comMannatech Reports Fourth Quarter 2024 Financial ResultsMarch 26, 2025 | businesswire.comMannatech Stock Soars to 52-Week High, Hits $16 MarkJanuary 30, 2025 | msn.comMannatech names Robert Toth vice chairman of the boardNovember 27, 2024 | markets.businessinsider.comMannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of DirectorsNovember 26, 2024 | businesswire.comMannatech Inc. Q3 Earnings SummaryNovember 13, 2024 | markets.businessinsider.comMannatech Reports Financial Results for Third Quarter 2024November 12, 2024 | businesswire.comTrading (MTEX) With Integrated Risk ControlsOctober 17, 2024 | news.stocktradersdaily.com(MTEX) Investment AnalysisOctober 6, 2024 | news.stocktradersdaily.comMannatech, Incorporated (NASDAQ:MTEX) Director Sells $126,232.00 in StockSeptember 12, 2024 | insidertrades.comDirector Tyler Rameson Acquires 16,288 Shares of Mannatech Inc (MTEX)September 11, 2024 | finance.yahoo.com(MTEX) Trading SignalsAugust 19, 2024 | news.stocktradersdaily.comMannatech Reports Financial Results for Second Quarter 2024August 13, 2024 | finance.yahoo.comHow To Trade (MTEX)July 29, 2024 | news.stocktradersdaily.com(MTEX) Long Term Investment AnalysisJuly 19, 2024 | news.stocktradersdaily.comMTEX Stock Earnings: Mannatech Reported Results for Q1 2024May 15, 2024 | investorplace.comMannatech Reports Financial Results for First Quarter 2024May 14, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTEX, CLLS, CLYM, and IZTC Company DescriptionsCellectis NASDAQ:CLLS$1.45 +0.01 (+0.49%) Closing price 05/30/2025 03:55 PM EasternExtended Trading$1.50 +0.06 (+3.94%) As of 05/30/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Climb Bio NASDAQ:CLYM$1.21 -0.01 (-0.82%) As of 05/30/2025 04:00 PM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Invizyne Technologies NASDAQ:IZTC$13.40 -0.50 (-3.60%) As of 05/30/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Mannatech NASDAQ:MTEX$9.86 +0.35 (+3.67%) Closing price 05/30/2025 03:58 PM EasternExtended Trading$9.86 +0.00 (+0.01%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
